Evidence Hub

Targeting Mitochondrial Dysfunction to Treat Diabetic Osteoporosis: Role of Neoprzewaquinone A.

Chen R, Yang C, Chen C, Yang F, Xiao H, Yang A, Peng B, Liu J et al.

Phytomedicine : international journal of phytotherapy and phytopharmacology, 2026

Abstract

BACKGROUND: Diabetic osteoporosis (DMOP) involves impaired bone formation driven by mitochondrial dysfunction and osteoblast apoptosis. Current treatments do not address these mechanisms.

OBJECTIVE: To evaluate whether Neoprzewaquinone A (NEO), a natural compound from Salvia miltiorrhiza, can protect bone by restoring mitochondrial integrity and activating survival signaling.

METHODS: Bioinformatics, molecular docking, and biophysical assays were combined with in vitro and in vivo studies. Mouse osteoblasts were exposed to glucolipotoxic conditions, and DMOP was induced in C57BL/6 mice. NEO's effects on mitochondrial morphology, mitochondrial membrane potential, ATP production, ROS, apoptosis markers, and PI3K/AKT/mTOR signaling were assessed using imaging, flow cytometry, western blotting, and micro-CT.

RESULTS: Glucolipotoxic stress caused mitochondrial damage, ROS accumulation, and suppression of ELF5/PRKD2 and PI3K/AKT/mTOR signaling. NEO bound PRKD2 with high affinity (KD ≈ 10⁻6 M), restored pathway activation, reduced ROS, attenuated HGPA-induced mitochondrial depolarization, restored ATP levels, and preserved mitochondrial ultrastructure. In diabetic mice, oral NEO improved bone mineral density, trabecular architecture, and mechanical strength without detectable toxicity.

CONCLUSION: NEO mitigates diabetic bone loss by rescuing mitochondrial function and activating the ELF5/PRKD2/PI3K/AKT/mTOR axis. These findings highlight mitochondrial protection as a promising…

Read the paper

Related studies

Go deeper in Evidence Hub

Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.

Open this study Sign up free